Where acute lymphoblastic leukemia treatment is heading
Acute lymphoblastic leukemia · Updated Nov 14, 2026
About 6,500 people in the US are diagnosed with acute lymphoblastic leukemia (ALL) each year, more than half of them children. About 90% of children are now cured with intensive chemotherapy, but adults do much worse. Immunotherapies (blinatumomab, inotuzumab, CAR T cells) and targeted pills are moving into first treatment, raising cure rates and, for some adults, replacing chemotherapy entirely.
- 628studies open or running
- 52phase 3 trials
- 1,946papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
Fewer relapses in childrenHappened 96.0% disease-free at 3 years
Adding blinatumomab: 96.0% disease-free at 3 years vs 87.9% with chemotherapy alone.
96.0%: disease-free at 3 years, vs 87.9% with chemotherapy alone.
Longer survival in adultsHappened 85% alive at 3 years
Blinatumomab added to consolidation: 85% alive at 3 years vs 68%.
85%: alive at 3 years, vs 68% with chemotherapy alone.
Chemotherapy-free treatment for Ph+ ALLHappened 86% event-free at 2 years
Ponatinib plus blinatumomab: 86% event-free at 2 years vs 67% with imatinib and chemotherapy.
86%: event-free at 24 months, vs 67% with imatinib plus chemotherapy.
A safer CAR T-cell therapy for adultsHappened 77% remission
Obe-cel put 77% into remission with few severe immune reactions; approved November 2024.
77%: overall remission rate.
-
6 months
by May 2027
Chemotherapy-free care enters guidelinesLikely 34.4% deep remission with ponatinib
Expect US guidelines and practice to adopt ponatinib plus blinatumomab for newly diagnosed Ph+ ALL.
34.4%: deep (MRD-negative) remission, vs 16.7% with imatinib.
-
12 months
by Nov 2027
Inotuzumab for young adultsPossible
An Alliance trial (303 people) adds inotuzumab to frontline chemotherapy for adolescents and young adults; due November 2027.
Another pill for Ph+ ALLPossible
POLARIS-1 (350 people) compares olverembatinib with imatinib; due December 2027.
-
3 years
by late 2029
A US chemotherapy-free trial for Ph+ ALLPossible
EA9181 (348 people) compares blinatumomab with chemotherapy, each with a TKI pill; due July 2028.
Gentler treatment for older adultsPossible
Amgen's Golden Gate (303 people) alternates blinatumomab with low-intensity chemotherapy; due September 2029.
-
5 years
by late 2031
Inotuzumab for high-risk childrenPossible 96.0% disease-free (blinatumomab)
The Children's Oncology Group's AALL1732 (5,951 children) adds inotuzumab for high-risk B-cell ALL; due March 2032.
96.0%: disease-free at 3 years, vs 87.9% with chemotherapy alone.
A next-generation T-cell engagerLong shot
Merck's MK-1045 (340 people) is compared directly with blinatumomab; due 2033.
The research paths
Immunotherapy in first treatment
96.0% disease-free at 3 yearsDetails and 4 trialsHide
Blinatumomab and inotuzumab added to or replacing chemotherapy.
WatchAALL1732; Alliance inotuzumab trial; Golden Gate.
- Inotuzumab for high-risk children (AALL1732)Children's Oncology Group · 5,951 people · enrolling Mar 2032
- Inotuzumab with frontline chemotherapy, young adultsAlliance · 303 people · enrolling Nov 2027
- Blinatumomab alternating with low-intensity chemotherapy, older adults (Golden Gate)Amgen · 303 people · fully enrolled Sep 2029
- MK-1045 (CD19 T-cell engager) vs blinatumomabMerck · 340 people · enrolling Oct 2033
Chemotherapy-free Ph+ ALL
86% event-free at 2 yearsDetails and 2 trialsHide
Potent TKI pills plus blinatumomab, replacing chemotherapy and often transplant.
WatchEA9181; POLARIS-1.
CAR T cells and targeted drugs at relapse
77% remissionDetails and 1 trialsHide
Safer CAR T cells and menin inhibitors for genetically defined subtypes.
WatchRevumenib in ALL.
Less treatment for low-risk children
Details and 1 trialsHide
Cutting chemotherapy where it adds little, to reduce long-term side effects.
WatchALLTogether1.
Borrowed from other cancers
From Chronic myeloid leukemia
Ponatinib
Approved
A third-generation BCR::ABL1 pill; Ph+ ALL shares the same fusion gene as CML.
From Acute myeloid leukemia
Revumenib
Approved
A menin inhibitor approved for KMT2A-rearranged acute leukemias of both types.
Open to join now
-
Newly diagnosed, young adults
Inotuzumab with chemotherapy
Locations and eligibility → -
High-risk children
Inotuzumab (AALL1732)
Locations and eligibility → -
Newly diagnosed Ph+ ALL
Olverembatinib
Locations and eligibility → -
B-cell ALL
MK-1045 vs blinatumomab
Locations and eligibility → -
Relapsed B-cell ALL
Surovatamig (CD19 T-cell engager)
Locations and eligibility →
See every recruiting ALL trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Chemotherapy-free ponatinib-blinatumomab beats chemo for Ph+ ALL
GIMEMA ALL2820, NEJM.
Blinatumomab cuts relapses in children
AALL1731, NEJM.
FDA approves obe-cel CAR T cells for adults
FELIX, NEJM.
Standard treatment today
- Children, B-cell ALLMulti-phase chemotherapy over 2-3 years; blinatumomab added for most.
- Adults, Ph-negativeIntensive chemotherapy plus blinatumomab; inotuzumab and transplant for higher risk.
- Adults, Ph-positiveA TKI pill (ponatinib or dasatinib) with blinatumomab or reduced chemotherapy.
- RelapsedBlinatumomab, inotuzumab, CAR T-cell therapy (tisagenlecleucel, brexucabtagene, obe-cel); revumenib for KMT2A-rearranged ALL.
How to read this page, and sourcesHow to read this page, and sources
- Children and adults are treated very differently, and Ph+ ALL differs from Ph-negative ALL; check which group a result applies to.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See ALL trials recruiting now →